Non-motor symptoms in Parkinson’s disease

Deutsche Zeitschrift für Nervenheilkunde - Tập 256 - Trang 293-298 - 2009
Ariane Park1, Mark Stacy2
1Department of Neurology, The Ohio State University, Columbus, USA
2Division of Neurology, Duke University Medical Center, Durham, USA

Tóm tắt

Parkinson’s disease is a hypokinetic movement disorder with cardinal motor features of bradykinesia, resting tremor and rigidity. However, non-motor symptoms, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances are gaining increasing attention. These non-motor symptoms may be intrinsic to the disease pathology or may be results of treatment with dopaminergic agents. Given that most, if not all, patients with Parkinson’s disease will experience non-motor symptoms, it is important to be sensitive to these phenomena, especially since some non-motor signs may precede motor impairment. Treatment may include interventions independent of traditional, dopaminergic anti-Parkinson therapy or may be tailored to increase or reduce dopamine responsiveness of the symptom.

Tài liệu tham khảo

Anonymous (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 340:757–763

Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56:730–736

Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72:708–712

Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18:287–293

Boeve BF, Dickson DW, Olson EJ, Shepard JW, Silber MH, Ferman TJ, Ahlskog JE, Benarroch EE (2007) Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 8:60–64

Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–1748

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211

Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV (2007) Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study. Mov Disord 22:2037–2042

Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 52:438–445

Brunton S, Kuritzky L (2005) Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 21:71–80

Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, Miano R, Finazzi-Agro E (2007) Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68:1455–1459

Cersosimo MG, Benarroch EE (2008) Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 23:1065–1075

Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 34:710–714

Cummings JL (1992) Depression and Parkinson’s disease: a review. Am J Psychiatry 149:443–454

de Groat WC (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 147(Suppl 2):S25–S40

Degen L, Petrig C, Studer D, Schroller S, Beglinger C (2005) Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 17:821–826

Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, Dell’Osso L, Bonuccelli U (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24:221–227

Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444

Diederich NJ, Raman R, Leurgans S, Goetz CG (2002) Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 59:1249–1252

Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1176–1177

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518

Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R (2003) Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 60:1756–1761

Fenelon G (2008) Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13:18–25

Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 21:2078–2081

Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171

Gagnon JF, Postuma RB, Montplaisir J (2006) Update on the pharmacology of REM sleep behavior disorder. Neurology 67:742–747

Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55:789–794

Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM (1998) Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50:515–517

Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71:371–374

Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM (1993) Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95:38–48

Kapoor S (2008) Management of constipation in the elderly: emerging therapeutic strategies. World J Gastroenterol 14:5226–5227

Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ (2004) Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1749–1752

Kaufmann H (2006) The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl 47:7–484

Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Gironell A, Garcia-Sanchez C, Martinez-Corral M (2008) Motor changes during sertraline treatment in depressed patients with Parkinson’s disease. Eur J Neurol 15:953–959

Kurlan R, Cummings J, Raman R, Thal L (2007) Quetiapine for agitation or psychosis in patients with dementia and Parkinsonism. Neurology 68:1356–1363

Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106(Pt 2):257–270

Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 19:1–8

Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277:1046–1051

Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ (2006) Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996–1002

Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O (2008) Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23:1361–1369

Ondo WG, Perkins T, Swick T, Hull KL Jr, Jimenez JE, Garris TS, Pardi D (2008) Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 65:1337–1340

Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350:786–799

Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R (2006) Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord 21:456–461

Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22:313–318

Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76:934–939

Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322

Sahai A, Khan MS, Arya M, John J, Singh R, Patel HR (2006) The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Expert Opin Pharmacother 7:529–538

Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46:388–393

Schestatsky P, Kumru H, Valls-Sole J, Valldeoriola F, Marti MJ, Tolosa E, Chaves ML (2007) Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69:2162–2169

Seeman P, Caruso C, Lasaga M (2008) Memantine agonist action at dopamine D2High receptors. Synapse 62:149–153

Stacy M (1999) Managing late complications of Parkinson’s disease. Med Clin North Am 83:469–481

Stacy M (2002) Sleep disorders in Parkinson’s disease: epidemiology and management. Drugs Aging 19:733–739

Stamey W, Davidson A, Jankovic J (2008) Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol 14:253–254

Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD (2005) Visual dysfunction in Parkinson disease without dementia. Neurology 65:1907–1913

Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ (2008) Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord 23:35–41

Wesnes KA, McKeith I, Edgar C, Emre M, Lane R (2005) Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65:1654–1656

Yamamoto T, Sakakibara R, Hashimoto K, Nakazawa K, Uchiyama T, Liu Z, Ito T, Hattori T (2005) Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience 135:299–303

Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C (2007) Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 22:1239–1244

Thông tin
Thông tin xuất bản

Deutsche Zeitschrift für Nervenheilkunde

Tập 256

293-298

Thông tin tác giả